Changes of soluble-Fas level in the optimal treatment of patients with chronic hepatitis B with poor antiviral response

doi:10.3877/cma.j.issn.1674-1358.2023.01.004

Abstract

Abstract:

Objective

To explore the correlation between dynamic changes of serum soluble-Fas (sFas) level in patients with chronic hepatitis B (CHB) during antiviral therapy and recovery of liver inflammation after control of hepatitis B virus (HBV) infection.

Methods

Total of 29 CHB patients with poor response to nucleoside (acid) analogues (CHB group) were collected from April 2011 to June 2014 in Department of Hepatology, Beijing Ditan Hospital. Meanwhile, 20 cases of HBV carriers were selected as HBV carrier group and 20 healthy volunteers were selected as control group, and the differences of serum sFas expression among the three groups were compared by high-throughput sequencing. According to different levels of HBV DNA, HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) at baseline of patients with CHB were divided into groups to compare the serum expression differences of sFas at 12, 24, 36 and 52 weeks after anti-HBV therapy.

Results

sFas levels of patients in CHB group [5.44 (3.49, 7.54) ng/ml] were higher than those of HBV carrier group [3.07 (1.82, 5.02) ng/ml] (Z = 3.070, P = 0.043) and control group [3.03 (2.12, 3.91) ng/ml](Z = 3.306、P = 0.019), with significant differences. The serum sFas level of patients with HBV DNA ≤ 10⁶ IU/ml was significantly higher than that of patients with HBV DNA > 10⁶ IU/ml during antiviral treatment [12 weeks: 6.67 (4.81, 9.11) ng/ml vs. 4.78 (3.00, 6.07) ng/ml: Z = 2.188, P = 0.0375; 36 weeks: 6.92 (3.56, 8.53) ng/ml vs. 3.68 (2.41, 5.04) ng/ml: Z = 2.515, P = 0.0182], with significant differences. The serum sFas level of patients with HBsAg ≤ 4 log₁₀IU/ml was significantly higher than that of patients with HBsAg > log₁₀IU/ml [baseline: 7.70 (4.75, 9.95) ng/ml vs. 4.78 (2.82, 6.33) ng/ml: Z = 2.922, P = 0.0069); 12 weeks: 7.70 (5.84, 10.11) ng/ml vs. 4.78 (3.16, 6.14) ng/ml: Z = 3.705, P = 0.001; 24 weeks: 6.98 (3.47, 10.37) ng/ml vs. 4.58 (3.38, 6.14) ng/ml: Z = 2.182, P = 0.038; 36 weeks: 6.92 (3.72, 8.73) ng/ml vs. 3.68 (3.06, 6.29) ng/ml: Z = 2.120, P = 0.0434; 52 weeks: 7.50 (3.81, 9.31) ng/ml vs. 4.02 (2.36, 7.53) ng/ml: Z = 2.267, P = 0.0316], with significant differences. The serum sFas level of patients with HBeAg ≤ 100 S/CO was significantly higher than that of patients with HBeAg > 100 S/CO [baseline: 7.50 (5.82, 10.26) ng/ml vs. 4.99 (2.66, 6.20) ng/ml: Z = 3.121, P = 0.0043; 12 weeks: 8.33 (6.95, 10.55) ng/ml vs. 4.78 (3.16, 6.33) ng/ml: Z = 3.976, P = 0.0005; 24 weeks: 7.62 (5.39, 10.77) ng/ml vs. 4.58 (3.23, 6.61) ng/ml: Z = 2.379, P = 0.0247; 36 weeks: 7.45 (5.33, 9.50) ng/ml vs. 3.68 (3.03, 5.21) ng/ml, with significant differences: Z = 2.966, P = 0.0062; 52 weeks: 7.50 (4.39, 9.72) ng/ml vs. 4.02 (2.01, 7.7) ng/ml: Z = 2.418, P = 0.0226], with significant differences. For patients with ALT > 40 U/L at baseline, sFas was positively correlated with alanine aminotransferase (ALT) (r = 0.234, P = 0.036).

Conclusions

sFas level of patients with CHB is higher than that of HBV carriers and healthy population. sFas levels decreased accordingly with the recovery of inflammation after anti-HBV treatment.

Key words: Chronic hepatitis B, Anti-viral therapy, Soluble-Fas

Min Quan, Gaiqing Yan, Huichun Xing. Changes of soluble-Fas level in the optimal treatment of patients with chronic hepatitis B with poor antiviral response[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(01): 16-23.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2023.01.004

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2023/V17/I01/16

Figures/Tables 7

References 26

[1]	Liu W, Guo TF, Jing ZT, et al. Repression of death receptor-mediated apoptosis of hepatocytes by hepatitis B virus e antigen[J]. Am J Pathol,2019,189(11):2181-2195.
[2]	李程, 王永康, 王昌源, 等. 乙型肝炎病毒X抗原表达与肝细胞凋亡的相关性[J]. 中华肝脏病杂志,2013,21(4):252-256.
[3]	Jing ZT, Liu W, Wu SX, et al. Hepatitis B virus surface antigen enhances the sensitivity of hepatocytes to fas-mediated apoptosis via suppression of AKT phosphorylation[J]. J Immunol,2018,201(8):2303-2314.
[4]	Wang Q, Na B, Ou JH, et al. Hepatitis B virus alters the antioxidant system in transgenic mice and sensitizes hepatocytes to Fas signaling[J]. PLoS One,2012,7(5):e36818.
[5]	Chen Z, Zhu Y, Ren Y, et al. Hepatitis C virus protects human B lymphocytes from Fas-mediated apoptosis via E2-CD81 engagement[J]. PLoS One,2011,6(4):e18933.
[6]	张启华, 许正锯, 程莉. 病毒性乙型肝炎患者血清sFas, TNF-α, IL-6和IL-8的检测及临床意义[J]. 细胞与分子免疫学杂志,2001,17(5):445-446.
[7]	刘龙, 刘遥, 高方媛, 等. 慢性肝病合并自身免疫性血液系统疾病的临床特征及应用糖皮质激素治疗效果分析[J]. 临床肝胆病杂志,2021,37(8):1878-1882.
[8]	魏来, 杨瑞锋. 乙型肝炎病毒e抗原定量检测的发展和意义[J]. 中华肝脏病杂志,2011,19(11):806-808.
[9]	Shata M, Abdel-Hameed EA, Rouster SD, et al. HBV and HIV/HBV infected patients have distinct immune exhaustion and apoptotic serum biomarker profiles[J]. Pathog Immun,2019,4(1):39-65.
[10]	张海萍, 闫惠平, 陈德喜, 等. 病原感染在自身免疫性肝病发生发展中的作用[J]. 临床肝胆病杂志,2022,38(4):754-758.
[11]	Raghuraman S, Abraham P, Daniel HD, et al. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection[J]. J Clin Virol,2005,34(1):63-70.
[12]	Zamani AG, Barlas IO, Durakbasi-Dursun G, et al. Evaluation of death pathway genes FAS and FASL polymorphisms in chronic HBV infection[J]. Int J Immunogenet,2013,40(6):482-487.
[13]	Bortolami M, Kotsafti A, Cardin R, et al. Fas/FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease[J]. J Viral Hepat,2008,15(7):515-522.
[14]	Karev VE. Fas, FasL, and bcl-2 expression on hepatic intralobar lymphocytes in different variants of the natural course of chronic HBV and HCV infection and in its outcomes[J]. Arkh Patol,2014,76(1):16-21.
[15]	宋修光, 杨公炜, 杜文军, 等. 乙型病毒性肝炎患者血清sFas水平检测及其临床意义[J]. 山东医药,2005,45(29):46-47.
[16]	宋修光, 马立宪. 乙型肝炎患者肝细胞Fas和血清可溶性sFas与肝脏损伤的关系[J]. 临床检验杂志,2007,25(1):32-33.
[17]	Lapiński TW, Kovalczuk O, Flisiak R, et al. Levels of HBV-DNA, sFas and sFasL among healthy HBsAg carriers in period of three years[J]. Adv Med Sci,2006,51:46-50.
[18]	Song le H, Binh VQ, Duy DN, et al. Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus[J]. J Med Virol,2004,73(2):244-249.
[19]	Jun EJ, Han JY, Sun HS. Clinical significances of serum soluble fas and soluble fas ligand in chronic hepatitis B[J]. Korean J Hepatol,2006,12(4):507-514.
[20]	Rivero M, Crespo J, Fábrega E, et al. Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus[J]. J Viral Hepat,2002,9(2):107-113.
[21]	Hasunuma T, Kayagaki N, Asahara H, et al. Accumulation of soluble Fas in inflamed joints of patients with rheumatoid arthritis[J]. Arthritis Rheum,1997,40(1):80-86.
[22]	Lapinski TW, Kowalczuk O, Prokopowicz D, et al. Serum concentration of sFas and sFasL in healthy HBsAg carriers, chronic viral hepatitis B and C patients[J]. World J Gastroenterol,2004,10(24):3650-3653.
[23]	El-Mesery M, El-Mowafy M, Youssef LF, et al. Serum soluble fibrinogen-like protein 2 represents a novel biomarker for differentiation between acute and chronic egyptian hepatitis B virus-infected patients[J]. J Interferon Cytokine Res,2021,41(2):52-59.
[24]	Silva JL, De Deus DM, Moreira RC, et al. The relationship between hepatitis B virus (HBV) load and levels of transforming growth factor beta 1 (TGF-β1) and soluble Fas (sFas) in human immunodeficiency virus patients with occult HBV infection[J]. Arch Virol,2015,160(7):1801-1804.
[25]	林向阳, 吴娅娅, 陶志华, 等. 肝硬化,肝癌患者血清sFas和TGF-β_1水平的探讨[J]. 中国实验诊断学,2005,9(1):102-104.
[26]	Liu W, Lin YT, Yan XL, et al. Hepatitis B virus core protein inhibits Fas-mediated apoptosis of hepatoma cells via regulation of mFas/FasL and sFas expression[J]. FASEB J,2015,29(3):1113-1123.

临床资料	CHB组（29例）	HBV携带组（20例）	对照组（20例）	统计量	P值
性别（例，男/女）	11/18	9/11	7/13	χ² = 1.153	0.071
年龄（岁）	31（20，59）	30.5（19，62）	27.6 ± 2.5	Z = 5.852	0.054
ALT（U/L）	47.4（13.9，152.5）	38.8（27.1，66.4）	11.5 ± 3.9	Z = 41.772	< 0.001
AST（U/L）	31.5（14.7，91.2）	22.1 ± 5.0	14.7 ± 2.8	Z = 40.540	< 0.001
TBil（μmol/L）	12.0（5.3，33.6）	10.7（27.9，7.4）	11.3（5.4，42.8）	Z = 2.287	0.319
DBil（μmol/L）	3.9（1.6，10.6）	3.5 ± 1.3	4.9（2.5，17.4）	Z = 6.109	0.047
ALB（g/L）	47.3（42.5，52.3）	48.9（44.9，57.3）	47.5（43.3，66.8）	Z = 4.343	0.114
HBV DNA（log₁₀IU/ml）	6.0 ± 1.3	8.1（2.0，8.4）	—	—	—
sFas（ng/ml）	5.44（3.49，7.54）	3.07（1.82，5.02）	3.03（2.12，3.91）	Z = 14.49	< 0.001

临床资料	CHB组（29例）	HBV携带组（20例）	对照组（20例）	统计量	P值
性别（例，男/女）	11/18	9/11	7/13	χ² = 1.153	0.071
年龄（岁）	31（20，59）	30.5（19，62）	27.6 ± 2.5	Z = 5.852	0.054
ALT（U/L）	47.4（13.9，152.5）	38.8（27.1，66.4）	11.5 ± 3.9	Z = 41.772	< 0.001
AST（U/L）	31.5（14.7，91.2）	22.1 ± 5.0	14.7 ± 2.8	Z = 40.540	< 0.001
TBil（μmol/L）	12.0（5.3，33.6）	10.7（27.9，7.4）	11.3（5.4，42.8）	Z = 2.287	0.319
DBil（μmol/L）	3.9（1.6，10.6）	3.5 ± 1.3	4.9（2.5，17.4）	Z = 6.109	0.047
ALB（g/L）	47.3（42.5，52.3）	48.9（44.9，57.3）	47.5（43.3，66.8）	Z = 4.343	0.114
HBV DNA（log₁₀IU/ml）	6.0 ± 1.3	8.1（2.0，8.4）	—	—	—
sFas（ng/ml）	5.44（3.49，7.54）	3.07（1.82，5.02）	3.03（2.12，3.91）	Z = 14.49	< 0.001

时间	H-DNA（13例）	L-DNA（16例）	Z值	P值
基线	4.68（2.82，5.94）	6.47（4.75，9.42）	1.778	0.0867
12周	4.78（3.00，6.07）	6.76（4.81，9.11）	2.188	0.0375
24周	3.68（3.23，5.44）	6.83（4.37，9.18）	1.810	0.0815
36周	3.68（2.41，5.04）	6.92（3.56，8.53）	2.515	0.0182
52周	4.02（2.94，6.57）	6.99（3.81，8.53）	1.690	0.1025

时间	H-DNA（13例）	L-DNA（16例）	Z值	P值
基线	4.68（2.82，5.94）	6.47（4.75，9.42）	1.778	0.0867
12周	4.78（3.00，6.07）	6.76（4.81，9.11）	2.188	0.0375
24周	3.68（3.23，5.44）	6.83（4.37，9.18）	1.810	0.0815
36周	3.68（2.41，5.04）	6.92（3.56，8.53）	2.515	0.0182
52周	4.02（2.94，6.57）	6.99（3.81，8.53）	1.690	0.1025

时间	H-sAg（17例）	L-sAg（12例）	Z值	P值
基线	4.99（2.82，6.33）	7.17（4.75，9.95）	2.922	0.0069
12周	4.78（3.16，6.14）	7.70（5.84，10.11）	3.705	0.0010
24周	4.58（3.38，6.14）	6.98（3.47，10.37）	2.182	0.0380
36周	3.68（3.06，6.29）	6.92（3.72，8.73）	2.120	0.0434
52周	4.02（2.36，7.53）	7.50（3.81，9.31）	2.267	0.0316

Please choose a citation manager

Content to export